ARM 24.174.1412. ADDITIONS, DELETIONS, AND RESCHEDULING OF DANGEROUS DRUGS

(1) In addition to those dangerous drugs scheduled in 50-32-222, 50-32-224, 50-32-226, 50-32-229, and 50-32-232, MCA, the board adds the following to dangerous drug schedules after considering federal regulations and/or the criteria enumerated in Title 50, chapter 32, part 2, MCA: (a) Schedule I: (i) none at this time; (b) Schedule II: (i) norfentanyl; (c) Schedule III: (i) none at this time; (d) Schedule IV: (i) brexanolone, allopregnanolone; (ii) soriamfetol; (iii) lemborexant; (e) Schedule V: (i) lasmiditan; (ii) cenobamate. (2) The board deletes the following dangerous drugs from the schedules in 50-32-222, 50-32-224, 50-32-226, 50-32-229, and 50-32-232, MCA, after considering federal regulations and/or the criteria enumerated in Title 50, chapter 32, part 2, MCA: (a) Schedule I: (i) none at this time; (b) Schedule II: (i) 6β-naltrexol; (c) Schedule III: (i) none at this time; (d) Schedule IV: (i) none at this time; (e) Schedule V: (i) approved cannabidiol drugs. A drug product in finished dosage formulation that has been approved by the United States Food and Drug Administration that contains cannabidiol, also known as (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol), derived from cannabis and no more than 0.1% (w/w) residual tetrahydrocannabinols, and as authorized by the Agriculture Improvement Act of 2018 (P.L. 115-334). (3) After considering federal regulations and/or the criteria enumerated in Title 50, chapter 32, part 2, MCA, the board reschedules the following dangerous drugs from those scheduled in 50-32-222, 50-32-224, 50-32-226, 50-32-229, and 50-32-232, MCA: (a) Schedule I: (i) none at this time; (b) Schedule II: (i) none at this time; (c) Schedule III: (i) none at this time; (d) Schedule IV: (i) none at this time; (e) Schedule V: (i) none at this time.